SCHEMBL939936

SCHEMBL939936

Nc1ccc(N2CCOCC2)cc1C(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 1/20 0.74
LGMN Q99538 4/20 0.59
SLC16A3 O15427 1/20 0.56
KMO O15229 1/20 0.55
PRKDC P78527 4/20 0.52
PIK3CD O00329 2/20 0.51
PIK3CA P42336 2/20 0.51
PIK3CB P42338 2/20 0.51
PIK3CG P48736 2/20 0.51
TBK1 Q9UHD2 1/20 0.51
MAPT P10636 3/20 0.50
ACLY P53396 1/20 0.48
KMT2A Q03164 4/20 0.47
KDM4E B2RXH2 3/20 0.47
GFER P55789 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144733 0.88 LGMN (0.59) IP6K1LGMNSLC16A3KMOPRKDC
SCHEMBL2420829 0.88 IP6K1 (0.56) IP6K1LGMNSLC16A3KMOPRKDC
SCHEMBL340945 0.86 PRKDC (0.67) IP6K1LGMNSLC16A3KMOPRKDC
SCHEMBL8976368 0.85 IP6K1 (1.00) IP6K1MAPTKMT2AKDM4EGFER
SCHEMBL7275734 0.85 PRKDC (0.60) IP6K1LGMNSLC16A3KMOPRKDC
SCHEMBL8871236 0.84 IP6K1 (0.97) IP6K1MAPTKMT2AKDM4EGFER
SCHEMBL16147346 0.83 PRKDC (0.61) IP6K1SLC16A3KMOPRKDCPIK3CD
SCHEMBL31536495 0.83 PRKDC (0.61) IP6K1SLC16A3KMOPRKDCPIK3CD
SCHEMBL9344830 0.82 LGMN (0.54) IP6K1LGMNPRKDCMAPTKMT2A
SCHEMBL1231926 0.82 LGMN (0.54) IP6K1LGMNPRKDCPIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071601-B2 Aminoquinoline derivatives and their use as adenosine A3 ligands SANOFI-AVENTIS (FR) 2011-12-06 US disclosed
US-20110112092-A1 AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI-AVENTIS (FR) 2011-05-12 US disclosed
CN-101239945-B Aminoquinoline derivatives and their use as adenosine a3 ligands SANOFI AVENTIS 2011-04-13 CN disclosed
US-20110009626-A1 AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI-AVENTIS (FR) 2011-01-13 US disclosed
US-7799922-B2 Aminoquinoline derivatives and their use as adenosine A3 ligands SANOFI-AVENTIS (FR) 2010-09-21 US disclosed
US-20090247745-A1 AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI-AVENTIS (FR) 2009-10-01 US disclosed
US-7547696-B2 Such as 4-methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]-benzamide; improved solubility SANOFI-AVENTIS (FR) 2009-06-16 US disclosed
CN-101239945-A Aminoquinoline derivatives and their use as adenosine a3 ligands SANOFI AVENTIS (FR) 2008-08-13 CN disclosed
CN-100402501-C Aminoquinoline derivatives and their use as adenosine A3Use of ligands SANOFI AVENTIS (FR) 2008-07-16 CN disclosed
EP-1663982-B1 AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI AVENTIS (FR) 2007-11-21 EP disclosed
CN-1829695-A Aminoquinoline derivatives and their use as adenosine A3Use of ligands SANOFI AVENTIS (FR) 2006-09-06 CN disclosed
EP-1663982-A1 AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS Sanofi-Aventis (FR) 2006-06-07 EP disclosed
WO-2005009969-A1 AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS SANOFI-AVENTIS (FR) 2005-02-03 WO disclosed
WO-2001044228-A2 DERIVATIVES OF QUINAZOLINEDIONE PHTHALIMIDE, PREPARATIONS THEREOF AND THEIR THERAPEUTIC USES SANOFI-SYNTHELABO (FR) 2001-06-21 WO disclosed
US-5616582-A Use as anticancer agents; e.g. gefitinib ZENECA LIMITED (GB) 1997-04-01 US disclosed
EP-0566226-B1 Quinazoline derivatives ZENECA LTD (GB) 1995-11-08 EP disclosed
US-5457105-A anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) ZENECA LIMITED (GB) 1995-10-10 US disclosed
EP-0566226-A1 Quinazoline derivatives ZENECA LIMITED (GB) 1993-10-20 EP disclosed
EP-0280187-B1 HAIR DYEING COMPOSITIONS WITH DIRECT-DYEING NITRO-DIPHENYL AMINE DERIVATIVES Henkel Kommanditgesellschaft auf Aktien (DE) 1992-01-02 EP disclosed
EP-0280187-A1 Hair dyeing compositions with direct-dyeing nitro-diphenyl amine derivatives Henkel Kommanditgesellschaft auf Aktien (DE) 1988-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247745-A1 AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS ADORA3, ADORA2A, ADORA1 IP6K1 1203/4885LGMN 4054/4885SLC16A3 523/4885
US-20110112092-A1 AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS ADORA3, ADORA2A, ADORA2B IP6K1 1518/4885LGMN 3849/4885SLC16A3 381/4885
US-20110009626-A1 AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS ADORA3, ADORA2A, ADORA2B IP6K1 782/4885LGMN 4109/4885SLC16A3 817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.